Effects of Ademetionine combined with Ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy
Objective:To observe effects of Ademetionine combined with Ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy.Methods:A prospective study was conducted on 76 patients with intrahepatic cholestasis of pregnancy admitted to the hospital from January 2019 to January 2023.According to the random number table method,they were divided into study group and control group,38 cases in each group.Both groups were given basic treatment.On this basis,the control group was treated with Ursodeoxycholic acid,while the study group was treated with Ademetionine on the basis of that of the control group.Both groups were treated for 14d.The clinical efficacy,the liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bile acid(TBA)]levels,the Itching degree[four-item itching questionnaire(FIIQ)]score,the inflammatory factors[interleukin-12(IL-12),interleukin-18(IL-18),tumor necrosis factor-α(TNF-α)]levels before and after the treatment,the incidence of adverse reactions,and the incidence of adverse maternal and infant outcomes were compared between the two groups.Results:The total effective rate of the study group was 94.74% (36/38),which was higher than 78.95% (30/38)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of ALT,AST and TBA in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the FIIQ score of the study group was lower than that of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of IL-12,IL-18 and TNF-α in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse maternal and infant outcomes in the study group was 5.26% (2/38),which was lower than 23.68% (9/38)in the control group,and the difference was statistically significant(P<0.05).However,there were no obvious adverse reactions in the two groups during the treatment.Conclusions:Ademetionine combined with Ursodeoxycholic acid in the treatment of the patients with intrahepatic cholestasis of pregnancy can improve the total effective rate of treatment,reduce the levels of liver function indexes,the itching scores,the inflammatory factor levels and the incidence of adverse maternal and infant outcomes.Moreover,it is superior to single Ursodeoxycholic acid treatment.
Intrahepatic cholestasis of pregnancyAdemetionineUrsodeoxycholic acidLiver functionItchingInflammatory factorAdverse maternal and infant outcome
万方数据
维普
